viernes, 2 de noviembre de 2012

WHO Pharmaceuticals Newsletter No. 5, 2012

indice



Regulatory Matters

Ambrisentan ........................................................................................ 4

Doripenem ........................................................................................ 4

Levofloxacin ................................................................................................ 4

Ondansetron ....................................................................................... 4

Paracetamol ................................................................................................ 5

Sildenafil ..................................................................................................... 6

Simvastatin ................................................................................................. 6

Statins........................................................................................................ 7

Strontium ranelate ....................................................................................... 7



Safety of medicines

Codeine ...................................................................................................... 9

Dipeptidylpeptidase-4 inhibitors (‘gliptins’)....................................................... 9

Over-The-Counter Topical Muscle and Joint Pain Relievers ................................. 10

Panitumumab ............................................................................................. 10

Paracetamol ............................................................................................... 10

Pramipexole ............................................................................................. 11

Oseltamivir ................................................................................................ 11

Quinolones ................................................................................................. 11



Signal

Ethinylestradiol/Drospirenone and Spinal cord infarction ................................... 13



Feature

The Global Fund to fight AIDS, TB and Malaria: An opportunity to

strengthen pharmacovigilance systems in beneficiary countries ......................... 15





disponible en

http://bit.ly/Rlrn2O